MIP-1095 is under clinical development by Progenics Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIP-1095’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MIP-1095 is under development for the treatment of metastatic castration-resistant prostate cancer. The drug candidate is an iodine-131-labeled prostate-specific membrane antigen (PSMA) targeted small molecule radiotherapeutic. Iodine-131 is a beta-particle-emitting radionuclide that is capable of destroying tumor cells. It is administered through intravenous route.
Progenics Pharmaceuticals overview
Progenics Pharmaceuticals is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics principal programs are directed toward supportive care, virology, human immunodeficiency virus, hepatitis C virus infections, and oncology. The company is headquartered in New York, New York, the US.
For a complete picture of MIP-1095’s drug-specific PTSR and LoA scores, buy the report here.